Fresenius Medical Care AG

SWX:FME Stock Report

Market Cap: CHF 9.4b

Fresenius Medical Care Valuation

Is FME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FME (CHF81.2) is trading below our estimate of fair value (CHF328.33)

Significantly Below Fair Value: FME is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FME?

Key metric: As FME is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for FME. This is calculated by dividing FME's market cap by their current earnings.
What is FME's PE Ratio?
PE Ratio18.7x
Earnings€530.26m
Market Cap€9.89b

Price to Earnings Ratio vs Peers

How does FME's PE Ratio compare to its peers?

The above table shows the PE ratio for FME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.7x
GALE Galenica
22.1x5.3%CHF 3.7b
YPSN Ypsomed Holding
66.2x32.9%CHF 5.2b
STMN Straumann Holding
62.8x20.9%CHF 18.1b
SOON Sonova Holding
31.6x8.6%CHF 19.0b
FME Fresenius Medical Care
18.7x22.2%CHF 9.9b

Price-To-Earnings vs Peers: FME is good value based on its Price-To-Earnings Ratio (18.7x) compared to the peer average (47.7x).

Price to Earnings Ratio vs Industry

How does FME's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
FME 18.7xIndustry Avg. 17.7xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: FME is good value based on its Price-To-Earnings Ratio (18.7x) compared to the European Healthcare industry average (18.7x).

Price to Earnings Ratio vs Fair Ratio

What is FME's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FME PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.7x
Fair PE Ratio40.9x

Price-To-Earnings vs Fair Ratio: FME is good value based on its Price-To-Earnings Ratio (18.7x) compared to the estimated Fair Price-To-Earnings Ratio (40.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FME forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CHF 37.10
0%
20.1%CHF 57.38CHF 24.86n/a18
Nov ’25n/a
CHF 37.10
0%
20.1%CHF 57.38CHF 24.86n/a18
Oct ’25n/a
CHF 37.10
0%
20.1%CHF 57.38CHF 24.86n/a18
Sep ’25n/a
CHF 37.10
0%
20.1%CHF 57.38CHF 24.86n/a18
Aug ’25CHF 81.20
CHF 37.10
-54.3%
19.6%CHF 57.02CHF 24.71n/a18
Jul ’25CHF 81.20
CHF 38.37
-52.7%
18.2%CHF 56.16CHF 24.96n/a19
Jun ’25CHF 81.20
CHF 39.55
-51.3%
18.3%CHF 57.95CHF 25.76n/a19
May ’25CHF 81.20
CHF 38.33
-52.8%
18.5%CHF 57.25CHF 25.44n/a19
Apr ’25CHF 81.20
CHF 37.90
-53.3%
19.2%CHF 56.91CHF 25.29n/a19
Mar ’25CHF 81.20
CHF 39.02
-51.9%
25.8%CHF 69.77CHF 24.85n/a20
Feb ’25CHF 81.20
CHF 37.93
-53.3%
25.8%CHF 66.19CHF 22.38n/a20
Jan ’25CHF 81.20
CHF 39.72
-51.1%
26.1%CHF 67.39CHF 22.78n/a19
Dec ’24CHF 81.20
CHF 39.93
-50.8%
26.0%CHF 67.66CHF 22.87n/a19
Nov ’24CHF 81.20
CHF 41.07
-49.4%
21.6%CHF 57.04CHF 22.81n/a18
Oct ’24CHF 81.20
CHF 42.84
-47.2%
22.3%CHF 64.25CHF 23.02n/a18
Sep ’24CHF 81.20
CHF 42.59
-47.5%
22.3%CHF 64.12CHF 22.97n/a19
Aug ’24CHF 81.20
CHF 39.24
-51.7%
27.3%CHF 64.25CHF 20.14CHF 81.2018
Jul ’24CHF 81.20
CHF 37.27
-54.1%
27.9%CHF 65.44CHF 20.51CHF 81.2017
Jun ’24CHF 81.20
CHF 36.02
-55.6%
31.2%CHF 65.24CHF 16.94CHF 81.2017
May ’24CHF 81.20
CHF 35.36
-56.5%
32.2%CHF 65.99CHF 17.14CHF 81.2016
Apr ’24CHF 81.20
CHF 33.41
-58.9%
33.2%CHF 65.68CHF 17.06CHF 81.2016
Mar ’24CHF 81.20
CHF 33.27
-59.0%
34.9%CHF 66.76CHF 17.34CHF 81.2015
Feb ’24CHF 81.20
CHF 32.63
-59.8%
36.0%CHF 66.68CHF 17.02CHF 81.2015
Jan ’24CHF 81.20
CHF 33.65
-58.6%
33.3%CHF 66.08CHF 16.86CHF 81.2015
Dec ’23CHF 81.20
CHF 33.76
-58.4%
34.3%CHF 66.00CHF 16.84CHF 81.2014
Nov ’23CHF 81.20
CHF 36.91
-54.5%
32.1%CHF 66.19CHF 16.89CHF 81.2015

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Becton Dickinson

US$66.7b

Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

912061

US$238.02

7D

0%

1Y

-2.2%

Abbott Laboratories

US$200.7b

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

ABT

US$93.50

7D

0%

1Y

2.7%

Galenica

CHF 3.7b

Operates as a healthcare service provider in Switzerland and internationally.

GALE

CHF 75.20

7D

-0.07%

1Y

7.6%